GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (FRA:TCE2) » Definitions » Common Stock

Celldex Therapeutics (FRA:TCE2) Common Stock : €0.06 Mil (As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Celldex Therapeutics Common Stock?

Celldex Therapeutics's quarterly common stock stayed the same from Mar. 2024 (€0.06 Mil) to Jun. 2024 (€0.06 Mil) but then declined from Jun. 2024 (€0.06 Mil) to Sep. 2024 (€0.06 Mil).

Celldex Therapeutics's annual common stock increased from Dec. 2021 (€0.04 Mil) to Dec. 2022 (€0.04 Mil) and increased from Dec. 2022 (€0.04 Mil) to Dec. 2023 (€0.05 Mil).


Celldex Therapeutics Common Stock Historical Data

The historical data trend for Celldex Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celldex Therapeutics Common Stock Chart

Celldex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.03 0.04 0.04 0.05

Celldex Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.05 0.06 0.06 0.06

Celldex Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Celldex Therapeutics Business Description

Traded in Other Exchanges
Address
53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Celldex Therapeutics Headlines

No Headlines